全文获取类型
收费全文 | 2947434篇 |
免费 | 230247篇 |
国内免费 | 5874篇 |
专业分类
耳鼻咽喉 | 42694篇 |
儿科学 | 91407篇 |
妇产科学 | 80665篇 |
基础医学 | 414259篇 |
口腔科学 | 84052篇 |
临床医学 | 264497篇 |
内科学 | 578586篇 |
皮肤病学 | 60494篇 |
神经病学 | 245865篇 |
特种医学 | 117934篇 |
外国民族医学 | 1129篇 |
外科学 | 449623篇 |
综合类 | 68561篇 |
现状与发展 | 1篇 |
一般理论 | 1169篇 |
预防医学 | 233749篇 |
眼科学 | 69395篇 |
药学 | 218688篇 |
59篇 | |
中国医学 | 5555篇 |
肿瘤学 | 155173篇 |
出版年
2018年 | 30022篇 |
2016年 | 25566篇 |
2015年 | 28897篇 |
2014年 | 41626篇 |
2013年 | 63566篇 |
2012年 | 85630篇 |
2011年 | 90430篇 |
2010年 | 53625篇 |
2009年 | 51485篇 |
2008年 | 86125篇 |
2007年 | 91463篇 |
2006年 | 92333篇 |
2005年 | 90139篇 |
2004年 | 86651篇 |
2003年 | 83805篇 |
2002年 | 82587篇 |
2001年 | 135246篇 |
2000年 | 139591篇 |
1999年 | 118261篇 |
1998年 | 34106篇 |
1997年 | 31072篇 |
1996年 | 30832篇 |
1995年 | 29618篇 |
1994年 | 27825篇 |
1993年 | 26047篇 |
1992年 | 94848篇 |
1991年 | 91521篇 |
1990年 | 88550篇 |
1989年 | 85348篇 |
1988年 | 79364篇 |
1987年 | 78129篇 |
1986年 | 74344篇 |
1985年 | 70862篇 |
1984年 | 53588篇 |
1983年 | 45731篇 |
1982年 | 27940篇 |
1981年 | 24733篇 |
1980年 | 23303篇 |
1979年 | 50263篇 |
1978年 | 35254篇 |
1977年 | 29865篇 |
1976年 | 28033篇 |
1975年 | 29780篇 |
1974年 | 36476篇 |
1973年 | 34696篇 |
1972年 | 32605篇 |
1971年 | 30128篇 |
1970年 | 28512篇 |
1969年 | 26605篇 |
1968年 | 24527篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
P. Herent B. Schmauch P. Jehanno O. Dehaene C. Saillard C. Balleyguier J. Arfi-Rouche S. Jégou 《Diagnostic and interventional imaging》2019,100(4):219-225
Purpose
The purpose of this study was to assess the potential of a deep learning model to discriminate between benign and malignant breast lesions using magnetic resonance imaging (MRI) and characterize different histological subtypes of breast lesions.Materials and methods
We developed a deep learning model that simultaneously learns to detect lesions and characterize them. We created a lesion-characterization model based on a single two-dimensional T1-weighted fat suppressed MR image obtained after intravenous administration of a gadolinium chelate selected by radiologists. The data included 335 MR images from 335 patients, representing 17 different histological subtypes of breast lesions grouped into four categories (mammary gland, benign lesions, invasive ductal carcinoma and other malignant lesions). Algorithm performance was evaluated on an independent test set of 168 MR images using weighted sums of the area under the curve (AUC) scores.Results
We obtained a cross-validation score of 0.817 weighted average receiver operating characteristic (ROC)-AUC on the training set computed as the mean of three-shuffle three-fold cross-validation. Our model reached a weighted mean AUC of 0.816 on the independent challenge test set.Conclusion
This study shows good performance of a supervised-attention model with deep learning for breast MRI. This method should be validated on a larger and independent cohort. 相似文献102.
Enhancement imaginaries: exploring public understandings of pharmaceutical cognitive enhancing drugs
AbstractThe growing use of psychoactive substances in everyday life, the increasing experimentation among users and the potential of poly drug use for non-medical, lifestyle or enhancement purposes presents an evolving policy challenge. The paper aims to build on previous research to gain a more in-depth qualitative understanding of the imaginaries around pharmaceutical cognitive enhancement (PCE). It focuses in particular on how the so-called pharmaceutical cognitive enhancing drugs (PCEDs) might be used and the social acceptability of these uses across multiple social contexts and groups. Data come from 23 focus groups (99 participants), representing a wide range of social groups, recruited in the UK. We discuss four distinct ‘enhancement practices’ where PCE use was conceptualised as a way to (1) become the best version of oneself; (2) gain a competitive edge over others; (3) for personal achievement or well-being; and (4) promote personal/public safety. The findings problematise the term ‘enhancement’ by showing the different ways in which the use of pharmaceutical ‘enhancement’ drugs can be imagined and understood. We argue for the value of policy responses that acknowledge and respond to a wider range of enhancement practices including those of prospective user groups. 相似文献
103.
104.
Andrew J Lindford Heikki Mäkisalo Hannu Jalanko Jouni Lauronen Veli-Jukka Anttila Susanna Juteau Antti-Jussi Ämmälä Anna Eskola Samuli Saarni Helena Isoniemi Antti Mäkitie Patrik Lassus 《Journal of plastic, reconstructive & aesthetic surgery》2019,72(2):173-180
Aim
We herein describe the establishment of the Helsinki Vascularized Composite Allotransplantation (VCA) program and its execution in the first two face transplant cases.Methods & patients
The Helsinki VCA program initially required the fulfillment of legal, hospital, financial, and ethical requirements. Thereafter, the assembling of a multidisciplinary team commenced. A team of Plastic, maxillofacial and ENT surgeons comprise the facial VCA team. The protocol involves collaboration with the Solid Organ Transplant (SOT) team, transplant immunology, immunosuppression, microbiology, psychiatric evaluation, well-defined VCA indications and informed consent. Between 2011 and 2017 two patients were selected for transplantation. Both patients had a severe composite facial deformity involving the maxilla and mandible following earlier ballistic injury.Results
Patient 1 was a 35 year-old male who underwent successful near total face transplantation in February 2016 and at 30 months he has a good aesthetic outcome with symmetrical restoration of the central face and good sensory and symmetrical motor functional outcomes. Patient 2 was a 58 year-old male who underwent full face transplantation in March 2018 and at 5 months he has recovered without major problems.Conclusion
A successful facial VCA program requires a well-prepared research protocol, experts from multiple specialties and careful patient selection. The establishment of the Helsinki VCA program required long and thorough planning and resulted in the first two Nordic face transplantation cases. This protocol now forms the platform (as a proof of concept) for other types of vascularized composite allotransplantations. 相似文献105.
106.
Evelien R. Spelten Chantal R. M. Lammens Vivian Engelen Saskia F. A. Duijts 《Journal of psychosocial oncology》2020,38(1):36-62
AbstractPurpose: While a wide range of psychosocial oncological (PO) interventions has been developed, a systematic overview of interventions to inform patients, care providers, as well as researchers, policy makers and health insurers, is lacking. The aims of this paper were (1) to describe the attainment of this overview, which may be used in other jurisdictions and for other health conditions and (2) to reflect on what determines developments in this field.Methods: Dutch researchers and care providers were invited to describe PO-interventions they apply in research or clinical practice. Selection criteria for what constituted a PO-intervention were determined. The input was organized in 12 predefined categories (e.g. physical functioning, genetics).Findings: Sixty-six PO-interventions were included in the overview. Two major categories were psychosocial functioning (24%) and physical functioning and recovery (24%). Interventions are mostly directed at adults (65%) and not aimed at a specific type of cancer (61%). Nearly 25% of the interventions lacked scientific underpinning.Conclusions: This paper provides an overview of Dutch PO-interventions and input on what drives their development. The categorizing method can be used in other jurisdictions and for other health care conditions. A next step would be to investigate the effectiveness and evidence of PO-interventions.Implications for Psychosocial Providers and Policy: The open access overview of interventions provides referral information for care providers. By identifying possible gaps and overlap, the overview looks at possible drivers behind developments in this field which will be of interest to policy makers. 相似文献
107.
K.A. Lee M.T.A. Sharabiani D. Tumino J. Wadsley V. Gill G. Gerrard R. Sindhu M.N. Gaze L. Moss K. Newbold 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(6):385-390
Aims
To obtain an overview of the management and outcomes of children aged 18 years or younger diagnosed with differentiated thyroid carcinoma of follicular cell origin across the UK, by collecting and analysing data from the limited number of centres treating these patients. This multicentre data might provide a more realistic perspective than single-institution series.Materials and methods
Six centres submitted data extracted from historical records on patients aged 18 years or younger, diagnosed between 1964 and 2017. The univariate and multivariable Cox proportional hazard model was used to identify potential predictors of progression-free survival, using national data as a control.Results
Data on 166 patients were available for analysis. Females (74%) were predominant, and the age ranged from 3 to 19 years at diagnosis, mean 14.1 years. Nodal metastases were present in 51%; 12% had distant metastases. After surgery, 95% received radioactive iodine (39% on more than one occasion) and 4% received external beam radiotherapy. With a median follow-up duration of 5 years, 69% are alive with no evidence of disease; 20% are alive with a raised thyroglobulin level as the only evidence of residual disease; 6% have residual structural disease detectable on imaging; 2% have died, from cerebral metastases.Conclusion
Despite most patients having advanced disease at presentation, outcomes are very good. A national prospective registry should allow systematic collection of good-quality data and may facilitate research to further improve outcomes. 相似文献108.
Edward J.A. Harris Steven Kao Brian McCaughan Takashi Nakano Nobuyuki Kondo Rebecca Hyland Anna K. Nowak Nicholas H. de Klerk Fraser J.H. Brims 《Journal of thoracic oncology》2019,14(2):288-293
Introduction
Malignant pleural mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centers to highly selected patients. A previously described classification and regression tree (CART) model stratified survival in unselected MPM patients using routinely collected clinical data. This study aimed to examine the performance of this CART model on a highly selected surgical population.Methods
Data were collected from subjects undergoing cytoreductive surgery for MPM from specialist centers in Hyõgo, Japan, and Sydney, Australia, between 1991 and 2016. The CART model was applied using the combination of clinical variables to stratify subjects into risk groups (1 through 4); survival characteristics were then compared.Results
Two hundred eighty-nine cases were included (205 from Australia, 84 from Japan). Overall median survival was 34.6 (interquartile range: 17.5–56.1) months; median age was 63.0 (interquartile range: 57.0–67.8) years, and 83.0% (n = 240) were male. There were no clinically meaningful differences between the two cohorts. Survival across the four risk groups was significantly different (p < 0.0001); the model stratified survival well with a Harrell's concordance statistic of 0.62 (95% confidence interval: 0.57–0.66) at 36 months. The group with the longest survival (median, 82.5 months) had: no weight loss, hemoglobin > 153 g/L and serum albumin > 43 g/L at time of referral to the surgical center.Conclusions
Using routinely available clinical variables, the CART model was able to stratify surgical patients into risk groups with statistically different survival characteristics with fair to good performance. Presence of weight loss, anemia, and low albumin should confer caution when considering surgical therapy for MPM. 相似文献109.
A. Glahn P. J. Proskynitopoulos S. Bleich T. Hillemacher 《Expert opinion on pharmacotherapy》2020,21(9):1083-1092
ABSTRACT
Introduction
Alcohol withdrawal syndrome is a common and life-threatening condition in patients suffering from alcohol use disorder. Treatment of this syndrome is challenging, especially in patients that are critically ill, either because of withdrawal symptoms or underlying conditions. For the treatment, several pharmacological agents exist, such as benzodiazepines, barbiturates, or dexmedetomidine. Nonetheless, as alcohol withdrawal syndromes can occur in every clinical setting, it is necessary to provide a guideline for clinicians confronted with this syndrome in varying clinical contexts. 相似文献110.